A Pharmacokinetic Study of Ustekinumab in Pediatric Subjects With Moderately to Severely Active Crohn's Disease

Completed · Phase 1

Conditions studied: Crohn Disease

In brief

The purpose of this study is to evaluate the pharmacokinetics (PK) of ustekinumab in subjects from 2 through less than (\<) 18 years old in the USA, or 6 through less than (\<) 18 years old in other countries and determine if it is similar to that observed in adults with moderately to severely active Crohn's disease (CD). Also to assess the safety, immunogenicity and efficacy of ustekinumab in the treatment of moderately to severely active CD. The main part of the study continues to Week 16, at which point all subjects who are receiving benefit from ustekinumab maintenance therapy (as determined by the investigator) are eligible to enter the long-term extension (LTE) and continue to receive ustekinumab. The study extension ends at Week 268 or upon availability of the LTE basket study (CNTO1275ISD3001) whichever occurs first. If participants do not consent/assent to the LTE basket study, they will continue safety follow-up for approximately 20 weeks after the last study agent administration.

Key facts

Study ID: NCT02968108
Run by: Janssen Research & Development, LLC
People needed: 45
Starts: 2017-01-18
Expected to finish: 2022-03-18
Last updated by the study team: 2025-04-27

Who can join

Age: 2 and older, up to 17. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Be a pediatric subject 2 to less than (<) 18 years old in the US, 6 to <18 years old elsewhere, of either gender with a body weight of greater than or equal to (>=) 10 kilogram (kg)
Have Crohn's disease (CD) or fistulizing CD of at least 3 months duration, with active colitis, ileitis, or ileocolitis, confirmed at any time in the past by radiography, histology, and/or endoscopy
Must have moderately to severely active CD defined by: Baseline pediatric Crohn's disease activity index (PCDAI) score of greater than (>)30 and at least one of the following: An abnormal C-reactive protein (CRP) >0.3 milligram per deciliter (mg/dL) or 3.0 milligram per liter (mg/L) at screening) or fecal calprotectin >250 milligram per kilogram (mg/kg) at screening or ileocolonoscopy with evidence of active CD (defined as ulcerations in the ileum and/or colon) during screening into this study including at the baseline visit
Prior or current medication for CD must include at least 1 of the following: Current treatment with at least 1 of the following therapies: oral corticosteroids, the immunomodulators azathioprine, 6-MP, or methotrexate, or currently have or have had a history of corticosteroid dependency, or have a history of failure to respond to, or tolerate, at least 1 of the following therapies including oral or IV corticosteroids or the immunomodulators 6-mercaptopurine, azathioprine, or methotrexate,or have required more than 3 courses of oral or IV corticosteroids in the past year
Have negative stool results for enteric pathogens. Stool studies must include a stool culture and Clostridium difficile toxin assay. These must have been performed during screening or the current episode of disease exacerbation as long as the stool studies were performed within 4 months prior to the first administration of study agent

You may not qualify if…

Has complications of CD such as symptomatic strictures or stenosis, short gut syndrome, or any other manifestation that might be anticipated to require surgery, could preclude the use of the PCDAI to assess response to therapy, or would possibly confound the ability to assess the effect of treatment with ustekinumab
Currently has or is suspected to have an abscess. Recent cutaneous and perianal abscesses are not exclusionary if drained and adequately treated at least 3 weeks prior to baseline, or 8 weeks prior to baseline for intra-abdominal abscesses, provided that there is no anticipated need for any further surgery. Participant with active fistulas may be included if there is no anticipation of a need for surgery and there are currently no abscesses identified
Has had any kind of bowel resection within 6 months or any other intra-abdominal surgery within 3 months prior to baseline
Has a draining (that is (i.e.), functioning) stoma or ostomy
Presence or history of any malignancy including presence or history of lymphoproliferative disease including lymphoma, or signs and symptoms suggestive of possible lymphoproliferative disease, such as lymphadenopathy of unusual size or location (example, nodes in the posterior triangle of the neck, infraclavicular, epitrochlear, or periaortic areas), or clinically significant hepatomegaly or splenomegaly

Where it is running

Cedars Sinai Medical Center — Los Angeles, California, United States
Connecticut Childrens Medical Center — Hartford, Connecticut, United States
Emory University — Atlanta, Georgia, United States
Children's Center For Digestive Healthcare, Llc — Atlanta, Georgia, United States
Methodist Medical Center of Illinois — Peoria, Illinois, United States
Mayo Clinic — Rochester, Minnesota, United States
Mount Sinai — New York, New York, United States
Childrens Hospital Of Philadelphia — Philadelphia, Pennsylvania, United States
Center For Digestive Health Systems-Greenville — Greenville, South Carolina, United States
Universitair Kinderziekenhuis Koningin Fabiola — Brussels, Belgium
Cliniques Universitaires Saint Luc — Brussels, Belgium
UZ Gent — Ghent, Belgium
UZ Brussel — Jette, Belgium
UZ Leuven — Leuven, Belgium
Stollery Children's Hospital — Edmonton, Alberta, Canada
British Columbia Children's Hospital — Vancouver, British Columbia, Canada
Children's Hospital of Western Ontario — London, Ontario, Canada
Hospital For Sick Children — Toronto, Ontario, Canada
Centre Hospitalier Sainte Justine — Montreal, Quebec, Canada
Hôpital Necker — Paris, France
Hôpital Robert Debré — Paris, France
Dr. von Haunersches Kinderspital — Munich, Germany
HELIOS Klinikum Wuppertal GmbH — Wuppertal, Germany
Instytut Centrum Zdrowia Matki Polki — Lodz, Poland
WIP Warsaw IBD Point Profesor Kierkus — Warsaw, Poland

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.